Why Did INTS Stock Plummet 25% Today?

• After the adjustment, Intensity Therapeutics stock will begin trading on February 19, retaining the ticker symbol INTS.
• The stock consolidation will reduce the total shares outstanding from approximately 63.3 million to about 2.53 million.
• In January, the company said it raised more than $20 million in 2025, extending its cash runway into the second quarter of 2027. 

Intensity Therapeutics, Inc. (INTS) on Friday announced a 1-for-25 reverse stock split approved by its board and shareholders, aiming to boost the per-share price of its common stock to meet Nasdaq’s minimum listing requirements.

The reverse split, scheduled to take effect at 4:01 p.m. ET on February 18, will consolidate every 25 existing shares into a single new share.

Changes After The Reverse Split

After the adjustment, Intensity Therapeutics stock will begin trading on February 19, under a new CUSIP number 45828J 202 while retaining the ticker symbol INTS.

Following the announcement, Intensity Therapeutics stock traded 25% lower on Friday morning. On Stocktwits, retail sentiment around the stock remained in ‘bullish’ territory amid ‘high’ message volume levels. 

Intensity is a late-stage biotech company developing its own cancer treatments. It uses a special drug-linking technology to create therapies that aim to destroy tumors and help the immune system better detect cancer.

Impact on Shareholders

The stock consolidation will reduce the total shares outstanding from approximately 63.3 million to about 2.53 million. No fractional shares will be issued; instead, shareholders entitled to a fraction will receive cash payments based on the adjusted closing price on February 18.

Alongside the split, the company will make proportional changes to stock options, warrants, convertible securities, and shares issued under its stock incentive programs. The total number of authorized shares will remain unchanged.

In January, the company outlined its 2025 achievements and mapped out priorities for 2026 as it advances INT230-6, its lead cancer therapy designed to destroy tumors and stimulate immune response. Intensity raised more than $20 million in 2025, extending its cash runway into the second quarter of 2027. 

INTS stock has declined by over 87% in the last 12 months. 

Also See: Tesla Stock Slips Premarket As EV Headwinds Mount — But One Wall Street Firm Sees Over 30% Upside On A ‘Physical AI’ Future

For updates and corrections, email newsroom[at]stocktwits[dot]com.

Share

·

Add us on